Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Posi ...Middle East

Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a 50.7% Objective Response Rate (ORR), 23.0-month Median Duration of Response (DOR), and Median Overall Survival (OS) of 18.4 months Safety findings consistent with prior studies with no reports of cytokine release...

Read More Details
Finally We wish PressBee provided you with enough information of ( Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Posi )

Also on site :

• Disney World Announces Opening Date for First Nighttime Parade in Nearly a Decade
• 'Law & Order' Fans Stunned by 'Girls Night Out' Photos of Mariska Hargitay and Kelli Giddish
• Mama June Shannon Quit Weight Loss Shots Cold Turkey—Here’s Why